Last reviewed 2026-04-20 · How we verify

Zolgensma

At a glance

Approved indications

• Spinal muscular atrophy

Common side effects

• Elevated aminotransferases
• ALT > 3 X ULN
• ALT > 20 X ULN
• Vomiting

Serious adverse events

• Thrombocytopenia
• Platelet count < 50,000 per µL
• Leukoencephalopathy
• Respiratory insufficiency
• Serious hypotension
• Seizures
• Death

Key clinical trials

• Single-Dose Gene Replacement Therapy Using for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies (PHASE3)
• Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1 (PHASE3)
• Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2 (PHASE3)
• Single-Dose Gene Replacement Therapy Clinical Trial for Participants With Spinal Muscular Atrophy Type 1 (PHASE3)
• Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy (PHASE1)
• Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials (PHASE3)
• Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam (PHASE3)
• Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA) (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.